Are Short Sellers On to Something at Navidea Biopharmaceuticals Inc (NAVB)? – Cardinal Health, Inc. (CAH)

Page 1 of 2

Since everyone loves a winner, it’s reasonable to assume that everyone hates a loser — everyone but short sellers, at least. These contrarian investors bet that hot stocks are primed to fall, aiming to turn their pessimism into profits.

Below, we take a look at biotech Navidea Biopharmaceuticals Inc (NYSEAMEX:NAVB), whose shares sold short, according to The Wall Street Journal, jumped 6%. That amounts to more than 17% of its float so its short interest ratio is 18 days to cover, or the number of days it would take to completely buy back all the shares sold short. The Motley Fool thinks seven days is a lot so it’s always possible we could see a short squeeze, but let’s see if the specialty pharma still has the power to make short work of short sellers.

Navidea Biopharmaceuticals snapshot

Market Cap $361 million
Revenues (TTM) >$1 million
1-Year Stock Return 4.7%
Estimated 5-Year EPS Growth N/A
Return on Investment (164.8%)
Dividend and Yield N/A
Recent Price $3.15
Shares Short Feb. 15 19.3 million
Shares Short Jan. 31 18.2 million
% Change 6.2%
CAPS Rating **

Sources: wsj.com, FinViz.com. N/A = not available; Navidea does not pay a dividend.

Just because the shorts are piling in doesn’t mean you should, too. Such stocks could have serious problems that warrant their short interest, but they might also just be stricken by short-term troubles. Only Foolish due diligence will tell you for certain.

Cardinal Health, Inc.The short story
Navidea Biopharmaceuticals Inc (NYSEAMEX:NAVB)’s lead product is Lymphoseek, a marker used to determine the spread of certain solid-tumor cancers into the lymphatic system, which has the potential to be a top-tier targeted imaging agent for lymphatic mapping. Following the disappointment associated with receiving a complete response letter from the FDA last September, Navidea finally has a PDUFA date at the end of next month that should determine once and for all whether it has addressed the regulatory agency’s concerns.

Fortunately, those issues centered on its contract manufacturing partners and not the imaging agent’s efficacy or safety, so considering it also filed a marketing authorization application with the European EMA, there might be some sense behind investors feeling confident that it has.

If the FDA does give Lymphoseek its imprimatur, Navidea and its U.S. marketing partner, Cardinal Health, Inc. (NYSE:CAH), plan to hit the ground running. There’s a worldwide market opportunity approaching $450 million, depending on who’s doing the counting, with the U.S. representing almost half of it at $200 million. The EU is second with $70 million, according to Navidea, and the rest of the world comes in at $180 million.

Of course, Navidea Biopharmaceuticals Inc (NYSEAMEX:NAVB) won’t recognize all that revenue because that’s just the addressable market. It’s going to have to split the proceeds with Cardinal Health, Inc. (NYSE:CAH), which also has the responsibility for determining what price to sell the agent (analysts have pegged it at around $400 per treatment ). As they’re also entitled to half the U.S. sales, it’s going to be a much smaller number that ends up on Navidea’s top line. Short sellers may agree there’s an opportunity here, but it’s likely a far smaller one than longs are suggesting.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

On the Move: The 10 Fastest Growing Businesses in 2015

Fast Money: The 10 Highest Paying Fast Food Restaurants

Mixing It Up: The 14 Best Music Mashups of 2014

Rito Pls Buff: The 10 Least Played Champions in LoL Season 4

10 Covers of Popular Songs that are Better than the Originals

Must See TV: The 9 Most Anticipated Shows of 2015

The 15 Biggest Box Office Bombs of All Time

10 Things The World Can’t Stand About Americans

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!